AI Better Than Human Eye At Predicting Brain Metastasis Outcomes

AI Better Than Human Eye At Predicting Brain Metastasis Outcomes

A recent study suggests an innovative AI technique they developed is considerably more effective than the human eye in predicting therapy outcomes in patients with brain metastases. The team hopes the new research and technology could eventually lead to more tailored treatment plans and better health outcomes for cancer patients.

“This is a sophisticated and comprehensive analysis of MRIs to find features and patterns that are not usually captured by the human eye,” says York Research Chair Ali Sadeghi-Naini, associate professor of biomedical engineering and computer science in the Lassonde School of Engineering, and lead on the study.

“We hope our technique, a novel AI-based predictive method of detecting radiotherapy failure in brain metastasis, will help oncologists and patients make better-informed decisions and adjust treatment in a situation where time is of the essence.”

Previous studies have shown that by using standard practices, such as MRI imaging — assessing the size, location — and several brain metastases — as well as the primary cancer type and overall condition of the patient, oncologists can predict treatment failure (defined as the continued growth of the tumour) about 65 per cent of the time. The researchers created and tested several AI models; their best one had an 83 per cent accuracy.

Brain metastases are a type of cancerous tumour that develops when primary cancers in the lungs, breasts, colon or other body parts are spread to the brain via the bloodstream or lymphatic system. While there are various treatment options, stereotactic radiotherapy is more common, with treatment consisting of concentrated doses of radiation targeted at the area with the tumour.

“Not all of the tumours respond to radiation — up to 30 per cent of these patients have continued growth of their tumour, even after treatment,” Sadeghi-Naini says. “This is often not discovered until months after treatment via follow-up MRI.”

This delay is the time patients with brain metastases cannot afford, as it is particularly debilitating, with most people succumbing to the disease between three months to five years after diagnosis. “It’s very important to predict therapy response even before that therapy begins,” Sadeghi-Naini continues.

Using a machine-learning technique known as deep learning, the researchers created artificial neural networks trained on a large data pool and then taught the AI to pay more attention to specific areas.

“When you look at an MRI, you see areas within or surrounding the tumour where the intensity and pattern is different, so you attend to those parts with your vision system more,” explains Sadeghi-Naini. “But an AI algorithm is blind to this. The attention mechanism we incorporated into the algorithm helps these AI tools to learn which part of these images are more important and put more weight on that for analysis and prediction.”

The study, now available online, has been published in the IEEE Journal of Translational Engineering in Health and Medicine. Partially funded by the Terry Fox Research Institute (TFRI), the modelling work was done at Sadeghi-Naini’s lab at York’s Keele Campus with York PhD student Ali Jalalifar, the first author of the study. When it came to data acquisition and interpretation of the results from more than 120 patients, the team could leverage York’s long-standing collaborative relationship with Sunnybrook Health Sciences Centre in Toronto. Other funders of the study included the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Hatch Memorial Foundation.

Sadeghi-Naini says that while more research needs to be done, the findings point to AI being a potentially significant tool in the precision management of brain metastasis and other types of cancer down the line.

The next step to adopting this as a clinical practice would be looking at a larger cohort with a multi-institutional data set, from there, a clinical trial could be developed. “If standard treatments can be tailored for patients based on their response to treatments — that can be predicted before treatment even starts — there’s a good chance that the overall survival of the patients can be improved,” he concludes.

As part of its long-standing program involving the best cancer researchers across Canada, the Terry Fox New Frontiers Program Project Grants, TFRI is funding further research in ultrasound and MRI for cancer therapy by Sadeghi-Naini and a team of clinicians and scientists based out of Sunnybrook Health Sciences Centre to the tune of $6 million over the next six years. Sadeghi-Naini is leading the biomedical computational-AI core of the program, receiving $900,000 of that funding.